NCT03428737

Brief Summary

The weaning of mechanical ventilation is difficult period. This period is particularly difficult for patient with obstructive chronic respiratory disease and a long mechanical ventilation is associated with an increased risk of infectious complication, cardiac dysfunction, muscular weakness or barotromatism. No guideline is available on the ventilator mode to use during the night. In weaning period, some studies have demonstrated that nocturnal control ventilation during the weaning period improved the quality and the quantity of sleep. The hypothesis is that use of nocturnal controlled mechanical ventilation could decrease the weaning period duration and the ventilation weaning failure because of a sleep improvement. The main objective is to compare mechanical ventilation weaning period duration according to the nocturnal ventilator mode (pressure controlled ventilation versus pressure support ventilation) in patients with an obstructive respiratory disease. A secondary objective is to evaluate the rate of weaning failure after the first extubation according to the nocturnal ventilator mode and to evaluate the sleep during the weaning period according to the nocturnal ventilator mode.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 5, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 12, 2018

Completed
1 year until next milestone

Study Start

First participant enrolled

March 1, 2019

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2022

Completed
Last Updated

May 10, 2023

Status Verified

May 1, 2023

Enrollment Period

3.1 years

First QC Date

February 5, 2018

Last Update Submit

May 9, 2023

Conditions

Keywords

pressure support ventilationpressure control ventilationsleep, weaningchronic obstructive respiratory diseaseweaning duration period

Outcome Measures

Primary Outcomes (1)

  • The percentage of ventilation weaning at Day 4

    at 4 day

Study Arms (2)

Nocturnal controlled pressure control ventilation

OTHER

use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night

Procedure: Nocturnal controlled pressure control ventilation

Nocturnal pressure support ventilation

OTHER

Use of a pressure support level identical during the night to the pressure support level at the end of the day.

Procedure: Pressure support ventilation

Interventions

use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night

Nocturnal controlled pressure control ventilation

use of a pressure support level identical during the night to the pressure support level at the end of the day.

Nocturnal pressure support ventilation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with invasive mechanical ventilation (with B840 ventilator)
  • Patient with ventilation weaning criteria
  • Patient able to support during the day pressure support ventilation with pressure support lower than 19 cm of H2O.
  • Patient with all mechanical ventilation weaning criteria for the first trial of spontaneous ventilation.
  • Age \> 18 years

You may not qualify if:

  • Patient with central apnoea syndrome
  • Patient with narcolepsy
  • Patient with metabolic encephalopathy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Amiens

Amiens, 80054, France

Location
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2018

First Posted

February 12, 2018

Study Start

March 1, 2019

Primary Completion

April 1, 2022

Study Completion

April 1, 2022

Last Updated

May 10, 2023

Record last verified: 2023-05

Locations